Cover Image
市場調查報告書

大腸癌症治療藥的亞太地區市場:2015年∼2019年

Colorectal Cancer Therapeutics Market in APAC 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 347445
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
大腸癌症治療藥的亞太地區市場:2015年∼2019年 Colorectal Cancer Therapeutics Market in APAC 2015-2019
出版日期: 2015年12月16日 內容資訊: 英文 106 Pages
簡介

亞太地區的大腸癌症治療藥市場,2014年∼2019年的年複合成長率,6.32%的成長被預料。

本報告提供亞太地區的大腸癌症治療藥市場相關調查分析、市場規模與成長率、市場趨勢、市場的推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 主要供應商產品
  • Vectibix

第3章 產品簡介

  • Stivarga
  • Erbitux
  • Xeloda
  • Avastin
  • Zaltrap

第4章 市場調查手法

  • 調查手法
  • 經濟指標

第5章 簡介

  • 主要市場焦點

第6章 疾病概要

  • 疾病的理解
  • 高危險因素
  • 徵兆與症狀
  • 病理生理學
  • 診斷
  • 分期
  • 生物標記檢驗
  • 流行病學
  • 治療

第7章 開發平台的組合

  • 開發平台候補相關資訊

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 日本市場
  • 中國市場
  • 波特的五力分析

第9章 市場區隔:各分子類型

  • 小分子
  • 生技藥品

第10章 市場區隔:各給藥途徑

  • 口服
  • 非口服

第11章 市場區隔:各化療

  • 一次治療
  • 二次治療

第12章 推動市場要素

第13章 推動因素的影響

第14章 市場課題

第15章 推動因素與課題的影響

第16章 市場趨勢

第17章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商
  • Amgen

第18章 主要供應商分析

  • Bayer HealthCare
  • Bristol-Myers Squibb
  • 中外製藥
  • Merck
  • Sanofi

第19章 附錄

  • 簡稱清單

第20章 關於Technavio

圖表

目錄
Product Code: IRTNTR7888

About colorectal cancer

Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio's analysts forecast the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.

Technavio's report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • APAC
  • China
  • Japan

Key vendors

  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • Chugai Pharmaceuticals
  • Merck
  • Sanofi

Other Prominent Vendors

  • Accord Healthcare
  • Advenchen Laboratories
  • Aeterna Zentaris
  • AstraZeneca
  • AVEO Oncology
  • Bavarian Nordic
  • Biothera
  • Boehringer Ingelheim
  • Boston Biomedical
  • Cancer Prevention Pharmaceuticals
  • Celator Pharmaceuticals
  • Daiichi Sankyo
  • Debiopharm
  • Eisai
  • Eli Lilly
  • EpicentRx
  • GlaxoSmithKline
  • Hutchison Medipharma
  • Immodulon Therapeutics
  • Immunomedics
  • MacroGenics
  • Merrimack Pharmaceuticals
  • MolMed
  • Mologen
  • Morphotek
  • Mylan
  • Nektar Therapeutics
  • Oncothyreon
  • Otsuka Pharmaceutical
  • PledPharma
  • Precision Biologics
  • PsiOxus Therapeutics
  • Sun Pharmaceutical
  • Symphogen
  • Taiho
  • Takeda
  • Teva Pharmaceuticals
  • ThromboGenics
  • Xbiotech
  • Yakult Honsha

Key market driver

  • Increase in aging population
  • For a full, detailed list, view our report

Key market challenge

  • Unknown disease etiology
  • For a full, detailed list, view our report

Key market trend

  • Rise in public awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Vectibix

PART 03: Product profiles

  • Stivarga
  • Erbitux
  • Xeloda
  • Avastin
  • Zaltrap

PART 04: Market research methodology

  • Research methodology
  • Economic indicators

PART 05: Introduction

  • Key market highlights

PART 06: Disease overview

  • Understanding the disease
  • High risk factors
  • Signs and symptoms
  • Pathophysiology
  • Diagnosis
  • Staging
  • Biomarker testing
  • Epidemiology
  • Treatment

PART 07: Pipeline portfolio

  • Information on pipeline candidates

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Colorectal cancer therapeutics market in Japan
  • Colorectal cancer therapeutics market in China
  • Five forces analysis

PART 09: Market segmentation by based on the type of molecules

  • Small molecules
  • Biologics

PART 10: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 11: Market segmentation by lines of chemotherapy

  • First-line chemotherapy
  • Second-line chemotherapy

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors
  • Amgen

PART 18: Key vendor analysis

  • Bayer HealthCare
  • Bristol-Myers Squibb
  • Chugai Pharmaceutical
  • Merck
  • Sanofi

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: High risk factors for colorectal cancer
  • Exhibit 03: Signs and symptoms of colorectal cancer
  • Exhibit 04: Diagnostic tests for colorectal cancer
  • Exhibit 05: Staging for colon cancer
  • Exhibit 06: Staging for rectal cancer
  • Exhibit 07: Types of genes
  • Exhibit 08: Estimated incidence, mortality, and five-year prevalence per 100,000 in APAC 2012
  • Exhibit 09: Colorectal cancer mortality rates in APAC 2012 (rate per 100,000 population)
  • Exhibit 10: Incidence rates of colorectal cancer in Asia, 2011 (rate per 100,000 population)
  • Exhibit 11: Estimated incidence in adult population in APAC 2012
  • Exhibit 12: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, males
  • Exhibit 13: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, females
  • Exhibit 14: Treatment options for colorectal cancer
  • Exhibit 15: Types of surgical procedure for colorectal cancer
  • Exhibit 16: Types of radiation therapy for colorectal cancer
  • Exhibit 17: Types of targeted therapy
  • Exhibit 18: Summary of approved cancer drugs for colon cancer
  • Exhibit 19: Pipeline molecules for colorectal cancer
  • Exhibit 20: Colorectal cancer therapeutics market in APAC ($ billions)
  • Exhibit 21: Colorectal cancer therapeutics market in Japan 2014-2019 ($ billions)
  • Exhibit 22: Colorectal cancer therapeutics market in China 2014-2019 ($ millions)
  • Exhibit 23: Five forces analysis
  • Exhibit 24: Colorectal cancer therapeutics market in APAC segmented by molecule type
  • Exhibit 25: Colorectal cancer therapeutics market in APAC segmented by route of administration
  • Exhibit 26: Summary of chemotherapy drugs for the treatment of colorectal cancer
  • Exhibit 27: Use of branded targeted therapies in China and Japan 2013
  • Exhibit 28: Drivers of colorectal cancer therapeutics market in APAC
  • Exhibit 29: Impact of drivers
  • Exhibit 30: Challenges of colorectal cancer therapeutics market in APAC
  • Exhibit 31: Impact of drivers and challenges
  • Exhibit 32: Trends of colorectal cancer therapeutics market in APAC
  • Exhibit 33: Vectibix: YoY revenue and growth rate in Japan 2011-2013 ($ millions)
  • Exhibit 34: Amgen: Key takeaways
  • Exhibit 35: Bayer: Key takeaways
  • Exhibit 36: Bristol-Myers Squibb: Key takeaways
  • Exhibit 37: Avastin: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
  • Exhibit 38: Xeloda: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
  • Exhibit 39: Chugai Pharmaceutical: Key takeaways
  • Exhibit 40: Merck: Key takeaways
  • Exhibit 41: Sanofi: Key takeaways
  • Exhibit 42: Amgen: Business segmentation by revenue 2014
  • Exhibit 43: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 44: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 45: Bayer HealthCare: Business segmentation by revenue 2014
  • Exhibit 46: Bayer HealthCare: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 47: Bayer HealthCare: Geographical segmentation by revenue 2014
  • Exhibit 48: Bristol-Myers Squibb: Products segmentation by revenue FY2014
  • Exhibit 49: Bristol-Myers Squibb: Revenue comparison by product segmentation by FY2013 and FY2014
  • Exhibit 50: Bristol-Myers Squibb: Geographical segmentation by FY2014 ($ millions)
  • Exhibit 51: Bristol-Myers Squibb: Revenue comparison by geographical segment by FY2013 and FY2014 ($ millions)
  • Exhibit 52: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
  • Exhibit 53: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
  • Exhibit 54: Merck: Business segmentation by revenue 2014
  • Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 56: Merck: Geographical segmentation by revenue 2014
  • Exhibit 57: Sanofi: Business segmentation by revenue 2014
  • Exhibit 58: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 59: Sanofi: Geographical segmentation by revenue 2014
Back to Top